Hepatitis Monthly

Published by: Kowsar

Hepatitis C Virus Seroprevalence and Associated Risk Factors Among Male Drug Injectors in Kermanshah, Iran

Asaad Sharhani 1 , 2 , Yadollah Mehrabi 1 , Alireza Noroozi 3 , 4 , Maryam Nasirian 5 , 6 , Peter Higgs 7 , Ahmad Hajebi 8 , Behrooz Hamzeh 9 , Nahid Khademi 10 , Mehdi Noroozi 11 , Ebrahim Shakiba 12 and Koorosh Etemad 1 , 2 , *
Authors Information
1 Department of Epidemiology, School of Public Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran
3 Psychiatrist, Iranian National Center for Addiction Studies (INCAS), Tehran University of Medical Sciences, Tehran, Iran
4 Department of Neuroscience and Addiction, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
5 Faculty of Biostatistics and Epidemiology Department, Health School, Isfahan University of Medical Sciences, Isfahan, Iran
6 HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran
7 Department of Public Health, La Trobe University, Bundoora 3083
8 Research Center for Addiction and Risky Behaviors (ReCARB), Psychiatric Department, Iran University of Medical Sciences, Tehran, Iran
9 Research Center for Environmental Determinants of Health, School of Public Health, Kermanshah University of Medical Sciences, Kermanshah, Iran
10 CDC Department, Kermanshah Health Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
11 Social Determinants of Health Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran
12 Department of Clinical Biochemistery, Kermanshah University of Medical Sciences, Kermanshah, Iran
Article information
  • Hepatitis Monthly: October 2017, 17 (10); e58739
  • Published Online: October 25, 2017
  • Article Type: Research Article
  • Received: July 25, 2017
  • Revised: September 1, 2017
  • Accepted: October 7, 2017
  • DOI: 10.5812/hepatmon.58739

To Cite: Sharhani A, Mehrabi Y, Noroozi A, Nasirian M, Higgs P, et al. Hepatitis C Virus Seroprevalence and Associated Risk Factors Among Male Drug Injectors in Kermanshah, Iran, Hepat Mon. 2017 ; 17(10):e58739. doi: 10.5812/hepatmon.58739.

Abstract
Copyright © 2017, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
Acknowledgements
Footnotes
References
  • 1. World Health Organisation. . Global hepatitis report. 2017;
  • 2. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013; 57(4): 1333-42[DOI][PubMed]
  • 3. Alter MJ, Gerety RJ, Smallwood LA, Sampliner RE, Tabor E, Deinhardt F, et al. Sporadic non-a, non-b hepatitis: Frequency and epidemiology in an urban U.S. Population. J Infect Dis. 1982; 145(6): 886-93[PubMed]
  • 4. Aceijas C, Stimson GV, Hickman M, Rhodes T, United Nations Reference Group on HP, Care among ID, et al. Global overview of injecting drug use and HIV infection among injecting drug users. AIDS. 2004; 18(17): 2295-303[PubMed]
  • 5. Aceijas C, Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy. 2007; 18(5): 352-8[DOI][PubMed]
  • 6. Amin-Esmaeili M, Rahimi-Movaghar A, Sharifi V, Hajebi A, Radgoodarzi R, Mojtabai R, et al. Epidemiology of illicit drug use disorders in Iran: prevalence, correlates, comorbidity and service utilization results from the Iranian Mental Health Survey. Addiction. 2016; 111(10): 1836-47[DOI][PubMed]
  • 7. Rahimi MA, Vameghi M. Social situation report of Iran (in Persian). 2011;
  • 8. Alavian S, Fallahian F. Epidemiology of hepatitis C in Iran and the world. SEMJ. 2009; 10(4): 162-72
  • 9. Amiri ZM, Rezvani M, Shakib RJ, Shakib AJ. Prevalence of hepatitis C virus infection and risk factors of drug using prisoners in Guilan province. EMHJ. 2007; 13(2)
  • 10. Mohammad Alizadeh AH, Alavian SM, Jafari K, Yazdi N. Prevalence of hepatitis C virus infection and its related risk factors in drug abuser prisoners in Hamedan--Iran. World J Gastroenterol. 2005; 11(26): 4085-9[PubMed]
  • 11. Alavi SM, Etemadi A. Hiv/hbv, hiv/hcv and hiv/htlv-1 co infection among injecting drug user patients hospitalized at the infectious disease ward of a training hospital in Iran. Pak J Med Sci. 2007; 23(4): 510-3
  • 12. Kheirandish P, SeyedAlinaghi S, Jahani M, Shirzad H, Seyed Ahmadian M, Majidi A, et al. Prevalence and correlates of hepatitis C infection among male injection drug users in detention, Tehran, Iran. J Urban Health. 2009; 86(6): 902-8[DOI][PubMed]
  • 13. Mir-Nasseri MM, Mohammadkhani A, Tavakkoli H, Ansari E, Poustchi H. Incarceration is a major risk factor for blood-borne infection among intravenous drug users: Incarceration and blood borne infection among intravenous drug users. Hepat Mon. 2011; 11(1): 19-22[PubMed]
  • 14. Mirahmadizadeh AR, Majdzadeh R, Mohammad K, Forouzanfar M. Prevalence of hiv and hepatitis c virus infections and related behavioral determinants among injecting drug users of drop-in centers in Iran. Iran Red Crescent Med J. 2009; 11(3): 325
  • 15. Nokhodian Z, Meshkati M, Adibi P, Ataei B, Kassaian N, Yaran M, et al. Hepatitis c among intravenous drug users in isfahan, Iran: A study of seroprevalence and risk factors. Int J Prev Med. 2012; 3: 131-8
  • 16. Garcia-Alvarez M, Berenguer J, Jimenez-Sousa MA, Pineda-Tenor D, Aldamiz-Echevarria T, Tejerina F, et al. Mx1, OAS1 and OAS2 polymorphisms are associated with the severity of liver disease in HIV/HCV-coinfected patients: A cross-sectional study. Sci Rep. 2017; 7: 41516[DOI][PubMed]
  • 17. Malekinejad M, Navadeh S, Lotfizadeh A, Rahimi-Movaghar A, Amin-Esmaeili M, Noroozi A. High hepatitis C virus prevalence among drug users in Iran: systematic review and meta-analysis of epidemiological evidence (2001-2012). Int J Infect Dis. 2015; 40: 116-30[DOI][PubMed]
  • 18. Rezaie F, Noroozi A, Armoon B, Farhoudian A, Massah O, Sharifi H, et al. Social determinants and hepatitis c among people who inject drugs in kermanshah, iran: Socioeconomic status, homelessness, and sufficient syringe coverage. J Subst Use. 2017; 22(5): 1-5
  • 19. Villano SA, Vlahov D, Nelson KE, Lyles CM, Cohn S, Thomas DL. Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J Clin Microbiol. 1997; 35(12): 3274-7[PubMed]
  • 20. Garfein RS, Doherty MC, Monterroso ER, Thomas DL, Nelson KE, Vlahov D. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr. 1998; 18
  • 21. Hagan H, Thiede H, Weiss NS, Hopkins S, Jeffrey S. D. , Alexander ER. Sharing of drug preparation equipment as a risk factor for hepatitis C. . Commun Dis Public Health. 2001; 91(1): 121-6
  • 22. Hahn JA, Page-Shafer K, Lum PJ, Bourgois P, Stein E, Evans JL, et al. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis. 2002; 186(11): 1558-64[DOI][PubMed]
  • 23. Hagan H, Thiede H, Des Jarlais DC. Hepatitis C virus infection among injection drug users: survival analysis of time to seroconversion. Epidemiology. 2004; 15(5): 543-9[PubMed]
  • 24. Esmaeili A, Mirzazadeh A, Carter GM, Esmaeili A, Hajarizadeh B, Sacks HS, et al. Higher incidence of HCV in females compared to males who inject drugs: A systematic review and meta-analysis. J Viral Hepat. 2017; 24(2): 117-27[DOI][PubMed]
  • 25. Ruta S, Cernescu C. Injecting drug use: A vector for the introduction of new hepatitis C virus genotypes. World J Gastroenterol. 2015; 21(38): 10811-23[DOI][PubMed]
  • 26. Wiessing L, Ferri M, Grady B, Kantzanou M, Sperle I, Cullen KJ, et al. Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PLoS One. 2014; 9(7): 103345[DOI][PubMed]
  • 27. Razaghi E, Rahimi-Movaghar A, Amin-Esmaeili M, Sahimi IE, Baghestani A. The study of prevalence of infectious diseases among injecting drug abusers and their correlated factors in Tehran in 2006-2007. 2008;
  • 28. Zamani S, Kihara M, Gouya MM, Vazirian M, Nassirimanesh B, Ono-Kihara M, et al. High prevalence of HIV infection associated with incarceration among community-based injecting drug users in Tehran, Iran. J Acquir Immune Defic Syndr. 2006; 42(3): 342-6[DOI][PubMed]
  • 29. Eckhardt B, Winkelstein ER, Shu MA, Carden MR, McKnight C, Des Jarlais DC, et al. Risk factors for hepatitis C seropositivity among young people who inject drugs in New York City: Implications for prevention. PLoS One. 2017; 12(5): 177341[DOI][PubMed]
  • 30. Page K, Morris MD, Hahn JA, Maher L, Prins M. Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. Clin Infect Dis. 2013; 57 Suppl 2-8[DOI][PubMed]
  • 31. Bagheri Amiri F, Mostafavi E, Mirzazadeh A. HIV, HBV and HCV Coinfection Prevalence in Iran--A Systematic Review and Meta-Analysis. PLoS One. 2016; 11(3): 151946[DOI][PubMed]
  • 32. World Health Statistics . Monitoring health for the SDGs sustainable development goals. 2016;
  • 33. Ventura M, Martin L, Jaubert C, Andreola ML, Masante C. Hepatitis C virus intragenomic interactions are modulated by the SLVI RNA structure of the core coding sequence. J Gen Virol. 2017; 98(4): 633-42[DOI][PubMed]
  • 34. Borba HH, Wiens A, Steimbach LM, Tonin FS, Pedroso M, Ivantes CA, et al. Rapid virological response of telaprevir and boceprevir in a Brazilian cohort of HCV genotype 1 patients: a multicenter longitudinal study. Ther Clin Risk Manag. 2017; 13: 59-64[DOI][PubMed]
  • 35. Ranieri R, Starnini G, Carbonara S, Pontali E, Leo G, Romano A, et al. Management of HCV infection in the penitentiary setting in the direct-acting antivirals era: practical recommendations from an expert panel. Infection. 2017; 45(2): 131-8[DOI][PubMed]
  • 36. Lloyd AR, Clegg J, Lange J, Stevenson A, Post JJ, Lloyd D, et al. Safety and effectiveness of a nurse-led outreach program for assessment and treatment of chronic hepatitis C in the custodial setting. Clin Infect Dis. 2013; 56(8): 1078-84[DOI][PubMed]
  • 37. Abdelmaksoud A. Anti-HCV for porphyria cutanea tarda. Dermatol Ther. 2017; 30(3)[DOI][PubMed]
  • 38. Mo H, Hedskog C, Lawitz E, Brainard DM, Yang J, Delaney W, et al. Antiviral response and resistance analysis of treatment-naive HCV infected patients receiving multiple doses of the NS3 protease inhibitor GS-9256. Antiviral Res. 2017; 140: 151-7[DOI][PubMed]
  • 39. Li X, Li Y, Fang S, Su J, Jiang J, Liang B, et al. Downregulation of autophagy-related gene ATG5 and GABARAP expression by IFN-lambda1 contributes to its anti-HCV activity in human hepatoma cells. Antiviral Res. 2017; 140: 83-94[DOI][PubMed]
  • 40. Abnet CC, Saadatian-Elahi M, Pourshams A, Boffetta P, Feizzadeh A, Brennan P, et al. Reliability and validity of opiate use self-report in a population at high risk for esophageal cancer in Golestan, Iran. Cancer Epidemiol Biomarkers Prev. 2004; 13(6): 1068-70[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments